Bengi Ruken Yavuz

Single-Cell Mapping of Malignant Signaling Networks Guides Drug Combinations

The paper identifies recurrent signaling pathways in breast cancer using single-cell data and suggests drug combinations targeting these pathways.

Oncogenic PI3Kα variants reveal graded conformational spectrum with mutation-specific cryptic pockets

The paper uses molecular dynamics simulations to show that double mutations in PI3K variants lead to more active conformations and drug-targetable cryptic pockets, suggesting a conformational selection strategy for drug development.

Cellular Mechanisms Underlying Melanoma Brain Metastasis

The paper identifies key molecular pathways and proteins associated with melanoma brain metastasis through genomic analysis and suggests therapeutic strategies targeting these pathways.

Anticancer Target Combinations: Network-Informed Signaling-Based Approach to Discovery

This paper develops a signaling-based method to identify optimal protein combinations for anticancer drug therapy, validated using patient-derived data and xenografts.

Co-occurring Mutations in Different Genes Can Fuel Oncogenic Signaling and Serve as Metastatic Tumor Markers

The paper identifies co-occurring mutation pairs in cancer genomes that are associated with metastasis and provides a tool for predicting metastatic potential.

Neurodevelopmental disorders and cancer networks share pathways; but differ in mechanisms, signaling strength, and outcome

This study compares neurodevelopmental disorders and cancer, finding shared pathways but differing in signaling strength and outcomes.

Discovery of Latent Drivers from Double Mutations in Pan-Cancer Data Reveal their Clinical Impact

The paper identifies latent driver double mutations in pan-cancer data and links them to clinical outcomes and drug response.